Session » Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

Date: Sunday, November 13, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1515

Assessing the Difference Between Radiographic Axial Spondylorthritis and Non-radiographic Axial Spondylorthritis in a Two-center Descriptive Study with Mexican Patients: The Influence of Clinical, Demographic, Laboratory and Clinimetric Features

1:00PM-3:00PM: Abstract Number: 1502

Assessment of Perceptions and Practices Regarding the Collaborative Management of Patients with Psoriatic Arthritis Among US Dermatology and Rheumatology Teams

1:00PM-3:00PM: Abstract Number: 1505

Blue-collar Workers with Psoriatic Arthritis: Disease Activity, Work Disability and Response to Biologics

1:00PM-3:00PM: Abstract Number: 1491

Clinically Relevant Differences in the Mobility of Patients with Axial Spondyloarthritis Related to Daytime of Performance

1:00PM-3:00PM: Abstract Number: 1501

Comparative Profiling of Serum Protein Biomarkers and Disease Activity Across Various Disease Domains in Patients with Psoriatic Arthritis (PsA)

1:00PM-3:00PM: Abstract Number: 1486

Derivation and Internal Validation of a Disease-specific Cardiovascular Risk Prediction Model for Patients with Psoriatic Arthritis and Psoriasis

1:00PM-3:00PM: Abstract Number: 1494

Determinants of Clinically Important Worsening in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort over 5 Years

1:00PM-3:00PM: Abstract Number: 1507

Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Outcome Measures in Psoriatic Arthritis

1:00PM-3:00PM: Abstract Number: 1487

Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

1:00PM-3:00PM: Abstract Number: 1496

Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met?

1:00PM-3:00PM: Abstract Number: 1504

Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Extensive Joint Involvement

1:00PM-3:00PM: Abstract Number: 1508

Enthesitis a Dominant Pathology in Psoriatic Arthritis: Identification and Quantification of Enthesitis Burden by 18F-FDG Total-Body PET/CT Imaging

1:00PM-3:00PM: Abstract Number: 1490

High Throughput Transcriptomic Analysis of Peripheral Mononuclear Cells Identifies Molecular Alterations Associated with the Active Clinical Phenotype of Axial Spondyloarthritis

1:00PM-3:00PM: Abstract Number: 1516

How Disease Activity Can Affect Workability in Spondyloarthropaties: A Monocentric Cohort Analysis

1:00PM-3:00PM: Abstract Number: 1495

How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study

1:00PM-3:00PM: Abstract Number: 1497

How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? – Real World Data from a German Observational Study with Secukinumab

1:00PM-3:00PM: Abstract Number: 1513

Identification of MRI Lesions Indicative of Spondyloarthritis Diagnosis from the Axial Spondyloarthritis International Society (ASAS) MRImagine Multi-Reader Scoring Dataset Using the Chi-Squared Automatic Interaction Detection Algorithm (CHAID)

1:00PM-3:00PM: Abstract Number: 1493

Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry

1:00PM-3:00PM: Abstract Number: 1489

Incidence of Herpes Zoster Events After the Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis

1:00PM-3:00PM: Abstract Number: 1488

Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriatic Arthritis: A Retrospective Cohort Study

1:00PM-3:00PM: Abstract Number: 1500

Investigating Serum Lipids Classifying Psoriatic Arthritis Disease Activity Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry

1:00PM-3:00PM: Abstract Number: 1503

Is Inflammation-driven Bone Loss Associated with Two-year Bone Formation at the Same Vertebra in Axial Spondyloarthritis? – a Multilevel MRI and Low Dose CT Analysis from the Sensitive Imaging of Axial Spondyloarthritis (SIAS) Cohort

1:00PM-3:00PM: Abstract Number: 1511

Is There a Correlation Between Skin and Musculoskeletal Activity in Psoriatic Arthritis

1:00PM-3:00PM: Abstract Number: 1510

Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of Tumour Necrosis Factor Inhibitors in Axial Spondyloarthritis – Data from 14 European Countries

1:00PM-3:00PM: Abstract Number: 1506

Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Population-Based Study

1:00PM-3:00PM: Abstract Number: 1509

Patient Clusters Identified by Machine Learning from a Pooled Analysis of the Clinical Development Program of Secukinumab in Psoriatic Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis with Axial Manifestations

1:00PM-3:00PM: Abstract Number: 1514

Self-referral Strategy for Early Diagnosis of Axial Spondyloarthritis- Preliminary Analysis from Finding Axial Spondyloarthritis Study

1:00PM-3:00PM: Abstract Number: 1498

The Association Between Sonographic Enthesitis with Sonographic Synovitis and Tenosynovitis in Psoriatic Arthritis

1:00PM-3:00PM: Abstract Number: 1499

The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control in Patients with Axial Spondyloarthritis: A Study from the CorEvitas PsA/SpA Registry

1:00PM-3:00PM: Abstract Number: 1492

Treatment with Non-steroidal Anti-inflammatory Drugs Is Associated with Retardation of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: 10-year Results from the GErman SPondyloarthritis Inception Cohort

1:00PM-3:00PM: Abstract Number: 1517

Value of the Anti-CD74 Antibodies for the Diagnosis of Axial Spondyloarthritis: Results of a Prospective Study in Patients with Suspicious Low Back Pain

1:00PM-3:00PM: Abstract Number: 1512

What Is the Best Referral Strategy for Axial Spondyloarthritis? A Prospective Multicenter Study of 515 Patients with Suspicious Chronic Low Back Pain

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].